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Background: In our research,we study the effect of 131iodine-labeled histamine-indomethacin (131I-His-IN). We focus
on its in vivo therapeutic effect and anti-tumor mechanisms in Lewis-bearing lung cancer.
Methods: 131I-His-IN was administered by garage to the mice. At different timepoints, we made autoradiography
(ARG) slices to observe the distribution of 131I-His-IN in the cellular, and the sliced samples underwent hematoxylin
and eosin (HE) staining for observation of tumor necrosis. Before treatment, the groups of mice underwent
18F-fluorodeoxyglucose (18F-FDG) positron emission tomography-computed tomography (PET-CT) scans ,and they
were then given physiologic saline, iodine 131 (131I), indomethacin (IN), Histamine-indomethacin (His-IN), and 131I-
His-IN, respectively, three times daily for seven days. Seven days later, all the mice underwent 18F-FDG PET-CT scans
again. We calculated the maximum standard uptake value (SUVmax) of the region of interest (ROI) and tumor
inhibition rate at the same time.
Results: In ARG groups, black silver particle was concentrated in the nucleus and cytoplasm. 131I-His-IN mainly
concentrated in tumor tissues. At 8 hours after 131I-His-IN, the radioactivity uptake in tumor tissue was higher than
in other organs (F=3.46,P<0.05). For the 18F-FDG PET-CT imaging, the tumor tissus’es SUVmax of the ROI was lower
compared to other groups after the treatment with 131I-His-IN. The tumor inhibitory rate (54.8%) in 131I-His-IN group
was higher than in other groups, too. In the 131I-His-IN group the vascular endothelial growth factor (VEGF)
decreased gradually compared to other groups. The tumor tissue necrotized obviously in 131I-His-IN group.
Conclusions: Through these animal experiments, we found 131I-His-IN could inhibit the Lewis lung cancer cells.
131I-His-IN focused at the cell nucleus and cytoplasm. It could reduce VEGF and increase tumor inhibitory rate. At
the same time, 18F-FDG PET-CT scan could be used for a curative effect and monitoring of disease prognosis.Background
Lung cancer is one of the most common malignant tu-
mors and is associated with a high mortality. The 5-year
survival rate after diagnosis is less than 13%, so early
and accurate diagnosis and appropriate treatment are
key factors in the prognosis of the disease. However,
conventional chemotherapy and radiotherapy do not al-
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reproduction in any medium, provided the orpharmacodynamic studies have reported that indome-
thacin, a nonsteroidal anti-inflammatory drug (NSAID)
with antirheumatic, antipyretic, and analgesic effect. It
also has certain antitumor effect. Studies have shown
indomethacin (IN) could strongly affinity and selectively
accumulate in the tumor tissue. In recent years, some
studies have successfully used a nuclide as a tumor mar-
ker for labeling of anti-tumor agents. The use of iodine131
(131I) radionuclide for labeling of indomethacin has been
rarely reported and its mechanism is still under study.
This study explores the mechanism of action and treat-
ment effects of 131I-histamine-indomethacin (131I-his-IN)
on Kunming mice inoculated with Lewis lung cancer cells.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Animals
The present study was carried out in the Experimental
Research Center, Sheng Jing Hospital of China Medical
University Hospital, Shenyang, China, between Decem-
ber 2010 and November 2011. The study was approved
by the Experimental Animal Committee of Sheng Jing
Hospital of China Medical University Hospital. Mouse
(n=6) Lewis lung cancer cells were obtained from the
China Academy of Medical Sciences, Institute of Materis
Medica, Beijing, China. Seventy-five Kunming mice (age
6–8 weeks; weight 20 ± 2 g) were purchased from the
Laboratory animal center, Shengjing Hospital of China
Medical University.
Main regents and instruments
Indomethacin, with a purity of 98.5%, was obtained
from YunPeng Linfen Shanxi pharmaceutical company.
Histamine-indomethacin (His-IN), with a purity of >95%,
was obtained from Shenyang Pharmaceutical University.
131I-his-IN was prepared using the method by Cai
Jiubo et al [1], with a purity of 95% and a specific
activity >185 GBq/g. Nuclear emulsion nuclear-4 was
purchased from the Institute of Modern Physics, Shanxi
Normal University.
In vivo mouse models with Lewis-bearing lung cancer
and groups
Lewis-bearing lung cancer mice were sacrificed when
the tumor size reached 1 to 1.5 cm in diameter. Growth
cell tumor tissue (10 g) was selected for grounding, and
cut into small pieces. The cell suspension was then di-
luted with 30 mL of physiological saline. Seventy-five
Kunming mice were inoculated by hypodermic needle at
the axillary skin of right forelimb with 0.2 mL of the cell
suspension containing approximately 2 × 106 cells.
When the tumor reached a maximum of 1.5 to 2.0 cm
in diameter, 75 of the Lewis-bearing lung cancer cell
Kunming mice were randomly divided into 15 groups
with 5 mice in each group. Each mouse was injected
intravenously at the tail with 2 mL 0.1% potassium iod-
ide within 3 days before inoculation in order to block
the thyroid gland. This procedure was done for 7 days,
three times per day.
Autoradiography (ARG) groups
Fifty of the Lewis-bearing lung cancer Kunming mice
were then divided into 10 groups randomly, with 5 mice
in each group. One group served as the control and was
injected with 0.2 mL physiological saline (group A), The
others 9 groups (groups B-J) were injected intravenously
with I131-His-IN at a dosage of 370 KBq (0.2 mL) at the
tail. After the injection, at different timepoint (B, 0.5 h;
C, 1 h; D, 2 h; E, 4 h; F, 8 h; G, 12 h; H, 24 h; I, 48 h;and J, 72 h), samples of ocular blood (0.2-mL) were col-
lected under anesthesia prior to sacrificing the animals.
Samples of the liver, kidney, blood, and muscles were
collected, washed with physiological saline, and dried by
filter paper. Those samples were then weighed. The ra-
dioactivity was measured using an R-well type counter
instrument. The percentage of radioactive counts per
gram of tissue (%ID) and the ratio of tumor tissue to
nontumor tissue were calculate.
The tumor tissue was made into ARG slices and HE
stained slices. For preparation of the ARG slices, tissue
was stored at 4°C for 24 hours. The slices were then de-
veloped and fixed, and HE dyed, then we observed the
distribution of silver particles with optical microscope.18F-FDG Positron emission tomography-computed
tomography (PET-CT) imaging
Twenty-five of the Lewis-bearing lung cancer cell
Kunming mice were divided into 5 groups randomly re-
spectively (5 mice in each group). They were: K (I131
group); L (IN group); M, (His-IN group); N (I131-His-IN
group), and O (physiological saline as the control group).
All the mice were injected with 3.7 MBq/200 μL of
18F-FDG into the tail intravenously. They were scanned
with 18F-FDG Positron emission tomography-computed
tomography (PET-CT) (GE Discovery DST 16 PET-CT,
USA). Then the test groups( from K to N) were treated
with different drug. For group K, 131I was injected locally
into the tumor site; Others the drug was instilled into
the stomach. The dosages for each group were: 0.2mL of
370 KBq for the 131I group, 0.4 mg/kg for the IN group,
0.4 mg/kg for the His-IN group, 0.2 mL of 370 KBq for
the 131I-His-IN group, and 0.2 mL of physiological saline
for the control group. This was carried out for 7 days
three times per day. 2 days after treatment, the mice
underwent 18F-FDG PET-CT imaging again.
To standardize imaging conditions and assure blood
glucose levels mice were fasted for at least 6 hours prior
to 18F-FDG-PET-CT imaging. The CT acquisition pa-
rameters were 130 kVp, 100 mAs, 1 second rotation, and
4 mm slice collimation at 8 mm/s bed speed. Approxi-
mately 60 minutes before imaging, mice were injected
intravenously with 3.7 MBq/200 μL of 18F-FDG. The dur-
ation of PET emission scan per bed position varied be-
tween 1 and 5 minutes as previously described. Care was
taken to assure a similar time interval from the injection
of FDG to the start of imaging for baseline and follow-up
studies. The CT images were reconstructed using
conventional filtered back-projection, at 3.4 mm axial in-
tervals to match the slice separation of the PET data.
PET images were reconstructed using iterative algo-
rithms Ordered Subset Expectation Maximization
(OSEM two iterations, eight subsets). To correct for
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Image Analysis: The Mirada workstation (REVEALMVS;
CTI Mirada Solutions, GE, USA) was used to view PET
and CT images. We also measured the FDG uptake of
tumor tissue. All FDG images were analyzed by two ob-
servers who were blinded to histopathological treatment
response. The single maximum pixel value within the slice
with the highest radioactivity concentration was detected
on baseline and follow-up scans as previously described.
The maximum standardized uptake value (SUVmax) was
calculated by dividing the activity in that pixel by the ad-
ministered dose normalized to mice body weight (g/mL).
One radiologist blinded to both PET and histopathological
response data measured tumor diameters on baseline and
follow-up CT images.
After scanning, the mice were anesthetized and ocular
blood samples (0.2 mL) were collected before the mice
were sacrificed. Tumor tissue samples were collected
and the tumor inhibitory rate was calculated using the
following formula:
Tumor inhibitory rate %ð Þ
¼ ð1 treatment group quality=
control group qualityÞ  100%
VEGF biomarker assays
Mouse blood samples were collected using serum separ-
ator tubes and were allowed to clot for 30 minutes prior
to centrifugation at 2000 g for 15 minutes. Serum sam-
ples were immediately stored at −80°C. Vascular endo-
thelial growth factor (VEGF) levels were measured in
duplicate for each serum sample using a commercially
available rat quantitative sandwich enzyme immunoassaya b
d e
Figure 1 Autoradiography (ARG) results for tumor tissue (HE×100). a:kits (ELISA) according to the manufacturer’s (Boster,
Wuhan, Hubei, China) instructions. For mouse serum
analysis, VEGF levels were measured using specific mouse
ELISA kits (R&D Systems, Boster, Wuhan, China). All bio-
marker assays were performed by blinded observers.
Statistical methods
The Statistical Package for Social Sciences Version 17.0
(SPSS inc., Chicago, IL, USA) statistical analysis software
was used for all statistical analyses of the results, and
data are expressed as mean±Standard deviation (SE). Two-
tailed t-tests and one-way analysis of variance (ANOVA)
with a Bonferroni correction for inter-group comparisons




For both the test and control groups, tumors were de-
tected at the local injection site, with the tumor for-
mation rate is 100%. For the ARG groups, black silver
particles were distributed in the tumor cell in all the
slices (see Figure 1) at different time points. At 4 hours,
the mean density of silver particles in the tumor tissue
was low and increased gradually. At 8 hours, the mean
density of the silver particles was the highest among the
groups. At 72 hours, an obvious decrease in the mean
silver particle density was observed. Through the ARG,
we observed that the silver particles were mainly distrib-
uted in the cytoplasm and cell nuclei; however, some
were also distributed in the cell membrane.
Distribution of 131I-His-IN in mice
Then from the in vivo distribution results and tumor/
non tumor (T/NT) ratio in mice bearing Lewis-lung can-
cer cells, it showed that 131I-His-IN was mostly distributedc
f
0.5 hour, b: 1 hour, c: 2 hour, d: 4 hour, e: 8 hour, f: 72 hour.
Figure 3 18F-FDG positron emission tomography-computed
tomography (PET-CT) maximum standard uptake value
(SUVmax) in treatment groups.
ba
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Figure 2). Eight hours later, the distribution of radio-
activity in tumor tissue reached its peak (52%). The
radioactivity distribution in extra-tumor tissue then
decreased gradually. The distribution of radioactivity
in tumor tissue, liver, kidneys, muscle, and blood dif-
fered significantly (F=3.46, P<0.05).
18F-FDG PET-CT Imaging
Before treatment, the ROI of tumor tissue SUVmax
was not different significanty (4.3 ± 1.3). After different
drugs’ treatment, the SUVmax of the tumor tissue in test
groups (from K to N groups) was reduced (3.73 ± 0.57)
compared with the control (4.85± 0.38). The difference
was statistically significant (F = 6.54, P < 0.05), with
131I-His-IN group reduced significantly (see Figure 3).
The rest groups (131I group, IN group, His-IN group)
were not different greatly.
Tumor inhibitory rate
Table 1 showed the variation in tumor volume between
the treatment groups and the control group of the
Lewis-bearing lung cancer mice during treatment. The
tumor growth for all groups was slow during treatment
after 7 days of treatment; growth inhibition was signifi-
cant (p<0.05) in the treatment groups compared with
the control. All treated groups showed a suppression of
Lewis tumor growth, especially for the131I-His-IN group.
VEGF level in ELISA
After 131I-His-IN was give the VEGF levels between
the 0.5-, 48-, and 72-hour groups were significantly dif-
ferent (P<0.05). After different treatments, VEGF levels
decreased significantly compared with the control groupFigure 2 131I-His-IN distribution in different organs.(F=7.74,P<0.05), especially for the 131I-His-IN and His-IN
groups.
Pathology
The diameter of tumors in mice bearing Lewis lung can-
cer tumors was between 1.5 cm and 2.0 cm; In HE-dyed
slices of the control group prior to treatment, the tumor
tissue was round and spindle, with a rich cytoplasm and
the nuclear in a circle with an obvious nucleoli, and with
more nuclear division. After treatment, necrosis of the
center of the tumor tissue gradually increased, especially
for the 131I-His-IN group (Figure 4, 5, 6).c d
Figure 4 Tumor tissue in HE pathology at 4 hours after
treatment (HE×40). a: Control, b: 131I, c: His-IN, d: 131I-His-IN.
Table 1 Weight and tumor inhibitory rates of tumors in
mice
Groups Tumor weight/g Tumor volume Tumor inhibitory
rate(%)
Control 4.3±1.43 5.84±1.25
131I* 3.74±0.57 3.68±0.84 27.1*
IN 3.51±0.62 3.45±0.47 30.4
His-IN 3.48±0.79 3.61±0.34 34.5
131I-His-IN 2.79±0.41 2.08±0.63 54.8
*131Iodine was injected into tumor tissue location.
a b
c d
Figure 6 Tumor tissue in HE pathology at 72 hours after
treatment (HE×40). a: Control, b: 131I, c: His-IN, d: 131I-His-IN.
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In recent years, A few research have reported that in-
domethacin has a sensitization and drug-resistant role
[2-5]. At the same time, indomethacin may affect the
tumor cell growth cycle, preventing increasement and
inducing apoptosis. It could update immune status and
stimulate the body to produce tumor necrosis factor
(TNF), interleukin (IL)-2, and interferon(INF) factors.
Thus, it could have both a direct anti-tumor effect and
assist in anti-tumor functions of other agents [6-8].
With the development of nuclear imaging technology,
ARG has played an important role in the understanding
of the effects of radioactive drugs at the cellular and
sub-cellular levels. It played an important role in re-
searching the metabolism and toxicology evaluations. It
could also assist in designing a clinical treatment plan.
In addition to its role for radioactive isotopes [9], ARG
also has biological characteristics, which can be used to
observe the quantitative distribution and exact positio-
ning of the cell, according to its biological metabolism.a
c d
b
Figure 5 Tumor tissue in HE pathology at 8 hours after
treatment (HE×40). a: Control, b: 131I, c: His-IN, d: 131I-His-IN.LiKun Zhou [10] et al applied tritium-labeled indometh-
acin and found indomethacin could focus on the cell
membrane, cytoblastema, and nucleus. Our study used
131I-His-IN in mice, with the ARG slices, finding the
drug targeted at the cell membrane, cell cytoplasm, and
the nucleus. The drug mainly distributed in the cyto-
plasm and nucleus. This result was similar to an earlier
report [10]. Research by ChunMei Chen [11] showed
that indomethacin can penetrate the bi-layer of the cell
membrane structure into tumor cells in the cytoplasm
and even the nucleus. Based on this finding, indometh-
acin may also have an anti-tumor role in the membrane,
cytoplasm, and the nucleus. In the cytoplasm, indometh-
acin may target the mitochondria directly, affecting its
energy metabolism or through oxidative phosphorylation
to affect the mitochondrial indirectly.
Other research [12] has shown that indomethacin may
work on drug resistance by inducing apoptosis, influen-
cing the energy metabolism of the mitochondria, espe-
cially oxidative phosphorylation. This latter effect may
increase the activity of oxygen by blocking the oxidative
phosphorylation, since the activity of oxygen was an im-
portant factor in suppressing tumor growth. Jiu bo Cai
[13] reported indomethacin could reverse lung cancer
cell drug resistance by improving 99 Tcm intake A549 /DDP
and inhibit MDRL and Pg-P expression.
The data of our research indicated that 131I-His-IN
was mostly distributed in the blood, liver, kidney, and
tumor tissue. At 8 hours, the distribution of radioactivity
in tumor tissue reached its peak (52%). The distribution
of radioactivity were differently among organs. At 72
hours, the radioactive count was reduced significantly,
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logical half-life of 131iodine. Kanfeng Liu [14] also re-
ported that 131I-His-IN was absorbed in the stomach
and then absorbed and stored in tumor tissues and ex-
creted via the kidney.
In our study, in PET-CT groups, the SUVmax was
greater than 2.5 (at 4.3 ±1.3) for the tumor tissue location
before treatment. After 7 days of treatment, 2 days later
the mice underwent 18 F-FDG PET-CT scanning again,
18F-FDG uptake of the ROI in the tumor site decreased
greatly. The SUVmax of the treated groups (3.73 + 0.58)
were lower than the control group (5. 3 + 0.43).
Our data suggested the SUVmax among the treatment
groups reduced differently, with 131 I-His-IN decreasing
significantly (F = 6.54, P < 0.05). This showed that
131I-His-IN inhibited tumor cells may through both
chemotherapy and radiation. The possible mechanisms
may include: indomethacin can gather specific nuclide
into tumor cells or on its surface as the carrier. At the
same time 131I emits nuclear rays (βparticles) aimed at
tumor tissue, killing the cancer cells; Indomethacin may
inhibit tumor chemical toxicity and enhance the nuclide
ionizing radiation effect. In the future, further study may
fucus on radiation-chemical-biological therapy com-
plexes, which would provide triple therapy to the tu-
mor locally. In addition, 131I could release γ rays, which
comprise single-photon emission computed tomography
(SPECT) imaging for tumor tissue [14].
The half-life of 131I is 8.06 days, which is helpful for
transportation and clinical application. In the procession
of decay, β、γ rays may be released, whose mainly ener-
gy at 610 keV and 364 keV spectively. Indomethacin
could carry 131I and aim it in the tumor site for a long
time, which preventing the damage to normal tissue or
other organs greatly, If 131 I-Hi-IN could be made into
anti-tumor targeting probe, which will become a hot
point for radiation therapy research.
Serum VEGF could be used in diagnosis, evaluation
before surgery, and monitoring of effective treatment and
prognosis for lung cancer. Angiogenesis is the growth and
metastasis of cells and the anatomical and physiological
basis for lung cancer. To inhibit angiogenesis is key in
controlling invasion and metastasis of cancer cells and this
inhibition could improve the prognosis and survival rates
for patients. Studies [15,16] have confirmed that VEGF
has a high expression in non-small cell and small cell lung
cancers. TianGang Xie et al [17] confirmed a high level of
expression of VEGF in peripheral blood for lung cancer
patients using ELISA methods. The preoperative level
was statistically different compared with a normal con-
trol group. Yang Dong Xia et al [18] research showed that
VEGF mainly expressed in the cytoplasm of lung cancer
cells, it showed a clear heterogeneity. It had a close re-
lationship with tumor angiogenesis. In our research, in131I-His-IN group, VEGF contents decreased gradually
over time. Statistical significance was seen among the
different timepoints (F = 5.48, P < 0.05), especially at
0.5 and 48 hours (P < 0.05). VEGF levels were re-
duced in the treatment groups compared with the control
group (F = 7.74, P < 0.05), with 131I-His-IN and His-IN
groups decreased greatly. These findings indicated that
131I-His-IN may have an antitumor role by reducing
VEGF level.
Conclusions
We observed that 131I-His-IN selectively accumulated in
the tumor tissue through ARG. 131I-His-IN was focused
on the nucleus and cytoplasm. It could reduce VEGF ex-
pression and increase tumor inhibitory rates. It contrib-
uted to necrosis of the tumor tissue. 131I-His-IN may
improve anti-tumor functions in the Lewis lung cancer.
18F-FDG PET-CT could be used for curative effects and
for monitoring the prognosis of lung cancer.
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